Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
01
2021
accepted:
07
05
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Healthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda. The survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information sources, underlying health conditions, and willingness-to-participate in COVID-19 vaccine trials. Data were analysed descriptively and a binomial generalised linear model with a log link function used to investigate factors associated with unwillingness to participate. 657 HCWs (female, 63%) were enrolled with a mean age of 33 years (Standard Deviation, 10). Overall willingness-to-participate was 70.2%. Key motivating factors for participation were: hope of being protected against COVID-19 (81.1%), altruism (73.3%), and the opportunity to get health care (26.0%). Selected hypothetical trial attributes reduced willingness-to-participate as follows: weekly-quarterly study visits over a 12-month period (70.2%-63.2%, P = 0.026); provision of approximately 50ml of blood at each study visit (70.2%-63.2%, P = 0.026); risk of mild-moderate local adverse reactions (70.2%-60.3%, P<0.001); chance of receiving candidate vaccine or placebo (70.2%-56.9%, P<0.001); and delay of pregnancy [Overall, 70.2%-57.1% P<0.001); Female, 62.8%-48.4% (P = 0.002); Male, 82.5%-71.5% (P = 0.003)]. Collectively, these attributes reduced willingness-to-participate from [70.2%-42.2% (P<0.001) overall; 82.5%-58.1% (P<0.001) in men; 62.8%-32.6% (P<0.001) in women]. Among individuals that were unwilling to participate, the commonest barriers were concerns over vaccine safety (54.6%) and fear of catching SARS-CoV-2 (31.6%). Unwillingness to participate was associated with being female (aRR 1.97, CI 1.46-2.67, P<0.001) and having university or other higher-level education (aRR 1.52, CI 1.05-2.2, P = 0.026). Willingness-to-participate in COVID-19 vaccine trials among HCWs in Uganda is high but may be affected by vaccine trial requirements and concerns about the safety of candidate vaccines.
Sections du résumé
BACKGROUND
Healthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda.
METHODS
The survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information sources, underlying health conditions, and willingness-to-participate in COVID-19 vaccine trials. Data were analysed descriptively and a binomial generalised linear model with a log link function used to investigate factors associated with unwillingness to participate.
RESULTS
657 HCWs (female, 63%) were enrolled with a mean age of 33 years (Standard Deviation, 10). Overall willingness-to-participate was 70.2%. Key motivating factors for participation were: hope of being protected against COVID-19 (81.1%), altruism (73.3%), and the opportunity to get health care (26.0%). Selected hypothetical trial attributes reduced willingness-to-participate as follows: weekly-quarterly study visits over a 12-month period (70.2%-63.2%, P = 0.026); provision of approximately 50ml of blood at each study visit (70.2%-63.2%, P = 0.026); risk of mild-moderate local adverse reactions (70.2%-60.3%, P<0.001); chance of receiving candidate vaccine or placebo (70.2%-56.9%, P<0.001); and delay of pregnancy [Overall, 70.2%-57.1% P<0.001); Female, 62.8%-48.4% (P = 0.002); Male, 82.5%-71.5% (P = 0.003)]. Collectively, these attributes reduced willingness-to-participate from [70.2%-42.2% (P<0.001) overall; 82.5%-58.1% (P<0.001) in men; 62.8%-32.6% (P<0.001) in women]. Among individuals that were unwilling to participate, the commonest barriers were concerns over vaccine safety (54.6%) and fear of catching SARS-CoV-2 (31.6%). Unwillingness to participate was associated with being female (aRR 1.97, CI 1.46-2.67, P<0.001) and having university or other higher-level education (aRR 1.52, CI 1.05-2.2, P = 0.026).
CONCLUSIONS
Willingness-to-participate in COVID-19 vaccine trials among HCWs in Uganda is high but may be affected by vaccine trial requirements and concerns about the safety of candidate vaccines.
Identifiants
pubmed: 34043693
doi: 10.1371/journal.pone.0251992
pii: PONE-D-21-01865
pmc: PMC8158909
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251992Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
AIDS. 1998 May 7;12(7):785-93
pubmed: 9619811
Vaccine. 2014 Oct 7;32(44):5854-61
pubmed: 25173475
Lancet Infect Dis. 2021 May;21(5):e114
pubmed: 33031753
Paediatr Respir Rev. 2020 Sep;35:43-49
pubmed: 32653463
Front Psychol. 2020 Oct 22;11:560828
pubmed: 33192827
Vaccine. 2020 Oct 21;38(45):7002-7006
pubmed: 32988688
BMC Health Serv Res. 2017 Dec 6;17(1):809
pubmed: 29207998
BMJ. 2020 Nov 9;371:m4347
pubmed: 33168562
AIDS Res Hum Retroviruses. 2009 Feb;25(2):217-24
pubmed: 19239362
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Virol J. 2021 Mar 17;18(1):58
pubmed: 33731169
Am J Prev Med. 2007 May;32(5):370-4
pubmed: 17478261
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
J Infect Dis. 2006 Jun 1;193(11):1598-605
pubmed: 16652290
Econ Disaster Clim Chang. 2020 Jul 23;:1-27
pubmed: 32838120
Global Health. 2020 May 15;16(1):46
pubmed: 32414379
Oncotarget. 2016 Sep 27;7(39):62898-62911
pubmed: 27588486
Vaccine. 2008 May 12;26(20):2528-36
pubmed: 18420313
Contemp Clin Trials Commun. 2017 Jun 24;7:122-125
pubmed: 29696176
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
BMJ. 2021 Feb 1;372:n296
pubmed: 33526412
Lancet. 2021 Feb 20;397(10275):642-643
pubmed: 33545098
JMIR Public Health Surveill. 2020 Oct 8;6(4):e21071
pubmed: 32936775
AJOB Empir Bioeth. 2019 Apr-Jun;10(2):79-87
pubmed: 31002583
Ann Intern Med. 2020 Dec 1;173(11):W156-W157
pubmed: 33085507
Gastroenterol Hepatol Bed Bench. 2013 Winter;6(1):14-7
pubmed: 24834239
JAMA. 2021 Apr 20;325(15):1575
pubmed: 33646285
Pharm Pract (Granada). 2016 Jan-Mar;14(1):708
pubmed: 27011778
Vaccine. 2013 Oct 17;31(44):5055-61
pubmed: 24021306
Prev Med Rep. 2021 Jun;22:101350
pubmed: 33816087
Trop Med Int Health. 2009 Feb;14(2):196-203
pubmed: 19207177
J Obstet Gynecol Neonatal Nurs. 2020 Sep;49(5):405-408
pubmed: 32800743
PLoS One. 2018 Nov 2;13(11):e0206656
pubmed: 30388145
J Acquir Immune Defic Syndr. 2004 May 1;36(1):604-12
pubmed: 15097304
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
PLoS One. 2017 Sep 7;12(9):e0183788
pubmed: 28880880
Front Public Health. 2020 Apr 30;8:181
pubmed: 32426320
Int J Environ Res Public Health. 2018 Aug 14;15(8):
pubmed: 30110896
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
BMJ. 2021 Mar 2;372:n597
pubmed: 33653708
Curr Genomics. 2015 Feb;16(1):47-59
pubmed: 25937813
PLoS One. 2016 Apr 01;11(4):e0152854
pubmed: 27035916
Contemp Clin Trials. 2011 May;32(3):342-52
pubmed: 21146635
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
AIDS Care. 2010 Nov;22(11):1403-9
pubmed: 20936540